fig4

Figure 4. Senolytic strategies eliminate STCs through apoptosis induction or immune-mediated mechanisms. (A) Targeting senescence-associated anti-apoptotic pathways (SCAPs), such as BCL-XL, using agents including navitoclax (ABT-263), dasatinib plus quercetin (D+Q), and fisetin. (B) The “one-two punch” strategy, in which senescence-inducing therapies are combined with senolytics to sequentially induce and eliminate STCs. (C) Immune-mediated clearance via targeting senescence-associated antigens or surface markers using CAR-T/CAR-NK cells or vaccination approaches.